Apyx Medical logo

APYX - Apyx Medical Share Price

$9.76 0.1  0.6%

Last Trade - 14/05/21

Small Cap
Market Cap £236.9m
Enterprise Value £209.1m
Revenue £22.3m
Position in Universe 3998th / 6849
Unlock APYX Revenue
Relative Strength (%)
1m +4.98%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -19.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
29.5 8.82 10.2 16.6 28.2 27.7 38.7 55.0 -1.3%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, ApyxMedical Corp revenues increased 73% to $8.6M. Net lossincreased from $2M to $4.9M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsSalaries and related costs increase of 28% to $4.2M(expense), Other loss / income, net decrease from $426K(income) to $93K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


APYX Revenue Unlock APYX Revenue

Net Income

APYX Net Income Unlock APYX Revenue

Normalised EPS

APYX Normalised EPS Unlock APYX Revenue

PE Ratio Range

APYX PE Ratio Range Unlock APYX Revenue

Dividend Yield Range

APYX Dividend Yield Range Unlock APYX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
APYX EPS Forecasts Unlock APYX Revenue
Profile Summary

Apyx Medical Corporation, formerly Bovie Medical Corporation, is an energy-based medical device company. The Company is engaged in the design, development and manufacturing of electrosurgical equipment by producing equipment for medical device manufacturers through original equipment manufacturing (OEM) agreements, as well as start-up companies. It operates through two segments: OEM and J-Plasma. It is engaged in developing and marketing a range of electrosurgical products and technologies, as well as related medical products used in doctor's offices, surgery centers and hospitals around the world. It also develops J-Plasma, a helium-based plasma surgical product. The J-Plasma system consists of an electrosurgical generator unit, a handpiece and a supply of helium gas. Its products are marketed through brands, including Aaron, DERM, IDS and ICON, and on a private label basis to distributors around the world. It offers products in electrosurgery, cauteries and other products categories.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated December 3, 1982
Public Since July 22, 1983
No. of Shareholders: 600
No. of Employees: 266
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 34,317,863
Free Float (0.0%)
Eligible for
APYX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for APYX
Upcoming Events for APYX
Friday 6th August, 2021 Estimate
Apyx Medical Corp Annual Shareholders Meeting
Monday 9th August, 2021 Estimate
Q2 2021 Apyx Medical Corp Earnings Release
Monday 8th November, 2021 Estimate
Q3 2021 Apyx Medical Corp Earnings Release
Frequently Asked Questions for Apyx Medical
What is the Apyx Medical share price?

As of 14/05/21, shares in Apyx Medical are trading at $9.76, giving the company a market capitalisation of £236.9m. This share price information is delayed by 15 minutes.

How has the Apyx Medical share price performed this year?

Shares in Apyx Medical are currently trading at $9.76 and the price has moved by 0.195k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Apyx Medical price has moved by 0.107k% over the past year.

What are the analyst and broker recommendations for Apyx Medical?

Of the analysts with advisory recommendations for Apyx Medical, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Apyx Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Apyx Medical next release its financial results?

Apyx Medical is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Apyx Medical dividend yield?

Apyx Medical does not currently pay a dividend.

Does Apyx Medical pay a dividend?

Apyx Medical does not currently pay a dividend.

When does Apyx Medical next pay dividends?

Apyx Medical does not currently pay a dividend.

How do I buy Apyx Medical shares?

To buy shares in Apyx Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Apyx Medical?

Shares in Apyx Medical are currently trading at $9.76, giving the company a market capitalisation of £236.9m.

Where are Apyx Medical shares listed? Where are Apyx Medical shares listed?

Here are the trading details for Apyx Medical:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: APYX
What kind of share is Apyx Medical?

Based on an overall assessment of its quality, value and momentum, Apyx Medical is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Apyx Medical share price forecast 2021?

Shares in Apyx Medical are currently priced at $9.76. At that level they are trading at 28.87% discount to the analyst consensus target price of 0.00.

Analysts covering Apyx Medical currently have a consensus Earnings Per Share (EPS) forecast of -0.563 for the next financial year.

How can I tell whether the Apyx Medical share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Apyx Medical. Over the past six months, the relative strength of its shares against the market has been 29.04%. At the current price of $9.76, shares in Apyx Medical are trading at 25.76% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Apyx Medical PE Ratio?

We were not able to find PE ratio data for Apyx Medical.

Who are the key directors of Apyx Medical?

Apyx Medical's management team is headed by:

Andrew Makrides - CHM
Moshe Citronowicz - SVP
Lawrence Waldman - LED
Michael Geraghty - IND
John Andres - VCH
Charles Goodwin - CEO
Craig Swandal - IND
Tara Semb - CFO
Todd Hornsby - EVP
Minnie Baylor-Henry - IND
Who are the major shareholders of Apyx Medical?

Here are the top five shareholders of Apyx Medical based on the size of their shareholding:

RTW Investments L.P. Investment Advisor/Hedge Fund
Percentage owned: 9.88% (3.39m shares)
Vanderfelt (William Weeks) Individual Investor
Percentage owned: 9.2% (3.16m shares)
Archon Capital Management LLC Hedge Fund
Percentage owned: 7.29% (2.50m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.45% (2.21m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.17% (1.43m shares)
Similar to APYX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.